Russia's Federal Medical-Biological Agency (FMBA) is preparing to begin clinical trials of a domestically developed vaccine against dengue fever.
The vaccine is designed to prevent one of the world's most widespread mosquito-borne viral diseases. According to the World Health Organization (WHO), more than half of the global population remains at risk of dengue infection.
The development of the Russian vaccine is part of the country's broader efforts to advance domestic biomedical technologies and expand its portfolio of modern preventive medicines.
The upcoming clinical trials are expected to evaluate the vaccine's safety and efficacy and will mark an important milestone in the development of Russian solutions aimed at strengthening infectious disease prevention and biological safety.
The vaccine is designed to prevent one of the world's most widespread mosquito-borne viral diseases. According to the World Health Organization (WHO), more than half of the global population remains at risk of dengue infection.
The development of the Russian vaccine is part of the country's broader efforts to advance domestic biomedical technologies and expand its portfolio of modern preventive medicines.
The upcoming clinical trials are expected to evaluate the vaccine's safety and efficacy and will mark an important milestone in the development of Russian solutions aimed at strengthening infectious disease prevention and biological safety.